Publication

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours

View document

Bibliographic Details
Summary:The expression of additional genes, other than oestrogen receptor (ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in close association with ERalpha, both encoding for transcription factors with a potential involvement in the ERalpha-mediated action in breast cancer. The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ERalpha-negative/poor prognosis breast cancer group.
Main Authors:Albergaria, André
Other Authors:Paredes, Joana; Sousa, Bárbara; Milanezi, Maria Fernanda Grillo; Carneiro, Vítor; Bastos, Joana; Costa, Sandra; Vieira, Daniella; Lopes, Nair; Lam, Eric W.; Lunet, Nuno; Schmitt, Fernando
Subject:Adult Aged Aged, 80 and over Disease-Free Survival Female GATA3 Transcription Factor Hepatocyte Nuclear Factor 3-alpha Humans Immunohistochemistry Middle Aged Prognosis Proportional Hazards Models Receptors, Estrogen Treatment Outcome Gene Expression Regulation, Neoplastic Ciências Médicas::Medicina Básica
Year:2009
Country:Portugal
Document type:article
Access type:open access
Associated institution:Universidade do Minho
Language:English
Origin:RepositóriUM - Universidade do Minho
Description
Summary:The expression of additional genes, other than oestrogen receptor (ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in close association with ERalpha, both encoding for transcription factors with a potential involvement in the ERalpha-mediated action in breast cancer. The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ERalpha-negative/poor prognosis breast cancer group.